Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update

Actimab-APositive

AI Analysis

Summary

Actinium Pharmaceuticals announced intellectual property and manufacturing advances for its Actimab-A program and provided an update on its NYSE American listing status.

Importance:3/10

Sentiment:

0.30

intellectual propertymanufacturingtargeted radiotherapyNYSE listing update

Related Companies

$ATNM

Read the original article

Published by PR Newswire Pharma on August 14, 2026 9:02 PM

Read Original